Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Submitted by admin on June 9, 2017 - 11:13am
Source: 
Endpoints
News Tags: 
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb
Headline: 
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

Do Not Allow Advertisers to Use My Personal information